Quality Management Systems for Biobanking
Biomedical investigators require high quality human tissue to support their research; thus, an important aspect of the provision of tissues by biorepositories is the assurance of high quality and consistency of processing specimens. This is best accomplished by a quality management system (QMS). The basis of a QMS program designed to aid biorepositories that want to improve their operations. In 1983, the UAB Tissue Collection and Biobanking Facility (TCBF) introduced a QMS program focused on providing solid tissues to support a wide range of research; this QMS included a quality control examination of the specific specimens provided for research. Similarly, the Division of Laboratory Sciences at the Centers for Disease Control and Prevention (CDC) introduced a QMS program for their laboratory analyses, focused primarily on bodily fluids. The authors of this article bring together the experience of the QMS programs at these two sites to facilitate the development or improvement of quality management systems of a wide range of biorepositories.
- Role of QMS in improving of biobank standards
- Forensic Study of Identity
- Sample integrity and quality assured biobanking
- Accreditation and Certification of Biobanks
- QMS implementation in maintenance and sustainability of biobanks
Related Conference of Quality Management Systems for Biobanking
21th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
16th International Conference on Human Genetics and Genetic Diseases
19th International Conference on Genomics & Pharmacogenomics
Quality Management Systems for Biobanking Conference Speakers
Recommended Sessions
- Biobanking Informatics
- Biorepository & Biospecimen
- Cryopreservation Methods
- Data Enrichment in Biobanks
- Ethical, legal and social issues in maintence of Biobanks
- Fertility biobanks
- Frontiers in Bioengineering and Biomaterials
- Germplasm Bank
- Next Generation Biobanking
- Quality Management Systems for Biobanking
- Stemcell Banking
- Tissue engineering
- Vitrification
Related Journals
Are you interested in
- 3D Bioprinting, Organ Fabrication & Bioartificial Tissues - Stem Cell 2026 (Netherlands)
- Aging Biology, Longevity Science & Cellular Rejuvenation - Stem Cell 2026 (Netherlands)
- Animal Genetics - Genome 2026 (Singapore)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioinformatics and Computational Biology - Genome 2026 (Singapore)
- Bioinformatics, AI Models & Predictive Regeneration - Stem Cell 2026 (Netherlands)
- Biomarkers and Microarrays - Genome 2026 (Singapore)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer Genomics - Genome 2026 (Singapore)
- Cancer Stem Cells & Targeted Therapeutics - Stem Cell 2026 (Netherlands)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiac, Vascular & Musculoskeletal Regeneration - Stem Cell 2026 (Netherlands)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Clinical genomics - Genome 2026 (Singapore)
- Clinical Translation of Stem Cell Therapies - Stem Cell 2026 (Netherlands)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- Commercialization, Biobanking & Industry Innovations - Stem Cell 2026 (Netherlands)
- Comparative Genomics - Genome 2026 (Singapore)
- Epigenomics and Epigenetics - Genome 2026 (Singapore)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Ethical, Regulatory & Quality Control Frameworks - Stem Cell 2026 (Netherlands)
- Exosomes, Extracellular Vesicles & Cell-Free Therapeutics - Stem Cell 2026 (Netherlands)
- Functional Genomics - Genome 2026 (Singapore)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Gene Editing and Genetic Engineering - Genome 2026 (Singapore)
- Gene Editing, CRISPR Therapies & Regenerative Genomics - Stem Cell 2026 (Netherlands)
- Genetic Disorder - Genome 2026 (Singapore)
- Genomic Instability - Genome 2026 (Singapore)
- Genomic Medicine - Genome 2026 (Singapore)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Microbial Genomics - Genome 2026 (Singapore)
- Next generation sequencing - Genome 2026 (Singapore)
- Nutrigenomics - Genome 2026 (Singapore)
- Personalized and Regenerative Medicine - Genome 2026 (Singapore)
- Pharmacogenomics - Genome 2026 (Singapore)
- Plant Genomics and Molecular Pharming - Genome 2026 (Singapore)
- Regeneration in Neurodegenerative & Spinal Cord Disorders - Stem Cell 2026 (Netherlands)
- Regenerative Approaches in Diabetes & Metabolic Disorders - Stem Cell 2026 (Netherlands)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Immunology & Immune Modulation - Stem Cell 2026 (Netherlands)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell Engineering & Cellular Reprogramming - Stem Cell 2026 (Netherlands)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)
- Structural Genomics - Genome 2026 (Singapore)
- Tissue Engineering, Biomaterials & Smart Scaffolds - Stem Cell 2026 (Netherlands)
- Trends in Genomics and Pharmacogenomics - Genome 2026 (Singapore)
